Canine Portosystemic Shunt: Diagnosis and Surgical Management

At a Glance

Classification of Portosystemic Shunts

Portosystemic shunts (PSS) are abnormal vascular connections that allow portal blood to bypass the liver and enter the systemic circulation directly. This bypass prevents the liver from processing toxins, nutrients, and drugs carried by portal blood, leading to a range of clinical signs. Shunts are classified as congenital or acquired, and further categorized by their anatomic location.

Congenital PSS are present at birth and result from failure of the ductus venosus to close or from abnormal vascular development. These shunts are single vessels that connect the portal vein or one of its tributaries to the systemic venous system. Congenital shunts are divided into extrahepatic and intrahepatic types. Extrahepatic shunts lie outside the liver parenchyma and are more common in small breed dogs such as Yorkshire Terriers, Maltese, and Miniature Schnauzers. Intrahepatic shunts course through the liver parenchyma and are more common in large breed dogs such as Golden Retrievers, Labrador Retrievers, and Irish Wolfhounds.

Acquired PSS develop secondary to chronic portal hypertension, typically from severe liver disease such as cirrhosis or hepatic fibrosis. These shunts are multiple, tortuous vessels that form as collateral circulation to decompress the portal system. Acquired shunts are not amenable to surgical attenuation and treatment focuses on managing the underlying hepatic disease.

The Merck Veterinary Manual provides a comprehensive overview of liver disorders in dogs, including portosystemic shunts, and is a standard reference for veterinary practitioners (Merck Veterinary Manual, www.merckvetmanual.com). The American College of Veterinary Internal Medicine (ACVIM) offers consensus statements and guidelines for the diagnosis and management of hepatobiliary disease in small animals (www.acvim.org).

Clinical Presentation and Signalment

History and Physical Examination Findings

Dogs with congenital PSS typically present at a young age, often before one year old. Owners may report stunted growth, poor body condition, and intermittent neurologic signs. Neurologic signs are the hallmark of hepatic encephalopathy and include lethargy, ataxia, circling, head pressing, blindness, seizures, and coma. These signs are often precipitated by a high-protein meal, gastrointestinal bleeding, or constipation, which increase the production of ammonia and other neurotoxins in the gut.

Gastrointestinal signs such as vomiting, diarrhea, and ptyalism are common. Urinary signs include pollakiuria, hematuria, and stranguria due to ammonium urate urolithiasis. Uroliths form because the liver cannot convert ammonia to urea, leading to hyperammonemia and increased renal excretion of ammonia, which combines with uric acid to form ammonium urate crystals.

On physical examination, affected dogs may be small for their age and have poor body condition. A cranial abdominal bruit may be auscultated over the shunt vessel. Neurologic examination may reveal dull mentation, ataxia, or other signs of forebrain dysfunction. Copper-colored irises have been described in some dogs with PSS, though this finding is not consistent.

Breed Predispositions

Certain dog breeds have a higher prevalence of congenital PSS. Extrahepatic shunts are overrepresented in Yorkshire Terriers, Maltese, Miniature Schnauzers, Havanese, and Pug dogs. Intrahepatic shunts are more common in Golden Retrievers, Labrador Retrievers, Irish Wolfhounds, and Australian Cattle Dogs. Breed-specific screening programs exist in some countries, and breeders should be aware of the heritable nature of this condition.

The American Animal Hospital Association (AAHA) provides resources on breed-specific health conditions and screening recommendations for veterinary practices (www.aaha.org/resources).

Diagnostic Approach

Laboratory Testing

Initial diagnostic evaluation begins with routine biochemistry, complete blood count, and urinalysis. Classic laboratory findings in dogs with PSS include decreased blood urea nitrogen (BUN) and creatinine due to reduced hepatic urea synthesis. Serum albumin and glucose may be low, reflecting decreased hepatic synthetic function. Liver enzyme activities, including alanine aminotransferase (ALT) and alkaline phosphatase (ALP), are often normal or mildly elevated.

Fasting and postprandial bile acid measurements are the most sensitive and specific serum tests for diagnosing PSS. Fasting bile acids are elevated in most affected dogs, but postprandial bile acids are more sensitive. A postprandial bile acid concentration above 25 to 30 µmol/L is highly suggestive of a PSS. Ammonia tolerance testing can also be used but is less commonly performed due to the risk of inducing hepatic encephalopathy.

Urinalysis may reveal ammonium urate crystals or uroliths. A urine specific gravity is often low due to medullary washout from the renal concentrating defect associated with liver disease.

Diagnostic Imaging

Abdominal ultrasound is the first-line imaging modality for suspected PSS. A skilled ultrasonographer can identify the shunt vessel, determine its location (extrahepatic vs. intrahepatic), and assess liver size and parenchyma. The liver is typically small and has a mottled echotexture. The portal vein may be hypoplastic or absent. Color flow Doppler is essential for identifying the direction of blood flow and confirming the shunt.

The study by Szatmari et al. (2004) on ultrasonographic diagnosis of portosystemic shunting in dogs and cats provides detailed methodology for ultrasound evaluation of these shunts (Veterinary Radiology & Ultrasound, 2004, PubMed ID 15487568). However, ultrasound has limitations. Operator experience is critical, and not all shunts are visible on ultrasound, particularly small extrahepatic shunts or those located deep within the liver.

Computed tomography angiography (CTA) is the gold standard for definitive diagnosis and surgical planning. CTA provides three-dimensional reconstruction of the portal and systemic vasculature, allowing precise identification of the shunt origin, insertion point, and course. This information is essential for selecting the surgical approach and predicting technical difficulty.

Nelson and Nelson (2011) described the anatomy of extrahepatic portosystemic shunts in dogs as determined by CT angiography, providing a classification system that aids surgical planning (Veterinary Radiology & Ultrasound, 2011, PubMed ID 21599793). A more recent multi-institutional study by the Society of Veterinary Soft Tissue Surgery and the Veterinary Interventional Radiology and Interventional Endoscopy Society classified extrahepatic shunts in 1082 dogs based on CT angiography, further refining the anatomic classification (Veterinary Radiology & Ultrasound, 2024, PubMed ID 39102361).

For intrahepatic shunts, CTA is particularly valuable. Bertolini et al. (2020) demonstrated that canine intrahepatic portosystemic shunt insertion into the systemic circulation is commonly through primary hepatic veins as assessed with CT angiography (Veterinary Radiology & Ultrasound, 2020, PubMed ID 32663370). This finding has implications for surgical planning, as the insertion point determines the approach for attenuation.

Advanced Imaging Considerations

CTA requires general anesthesia and intravenous contrast administration. The procedure carries risks in dogs with compromised hepatic function, including potential for contrast-induced nephropathy and exacerbation of hepatic encephalopathy. Pre-anesthetic stabilization with medical therapy is essential before CTA.

Magnetic resonance angiography is an alternative imaging modality but is less commonly used due to longer anesthesia time and higher cost. Portal scintigraphy using technetium-99m pertechnetate can quantify the degree of shunting but does not provide anatomic detail for surgical planning.

Medical Management

Preoperative Stabilization

Medical management is indicated for all dogs with suspected or confirmed PSS before surgical attenuation. The goals of medical therapy are to reduce the production and absorption of neurotoxins, control clinical signs of hepatic encephalopathy, and improve the dog's overall condition for anesthesia and surgery.

Dietary modification is the cornerstone of medical management. A low-protein diet with high-quality, highly digestible protein sources is recommended. Commercial hepatic support diets are available and are formulated to meet the nutritional needs of dogs with liver disease while minimizing protein load. Protein restriction should be individualized, excessive restriction can lead to malnutrition and worsen hepatic function.

Lactulose is a non-absorbable disaccharide that acidifies the colonic lumen, trapping ammonia as ammonium ions and promoting its excretion in feces. Lactulose also has a cathartic effect, reducing the transit time of colonic contents and decreasing ammonia absorption. The typical starting dose is 0.5 to 1 mL per kg of body weight orally every 8 to 12 hours, titrated to produce two to three soft stools per day.

Antibiotics such as metronidazole or amoxicillin are used to reduce the population of urease-producing bacteria in the colon, thereby decreasing ammonia production. Metronidazole also has anti-inflammatory properties that may benefit the liver. Antibiotic therapy is typically continued for 7 to 14 days before surgery.

Emergency Management of Hepatic Encephalopathy

Dogs presenting with acute hepatic encephalopathy require aggressive medical management. Intravenous fluids with dextrose supplementation are administered to correct dehydration and provide energy. Lactulose can be given as a retention enema (1:3 dilution with warm water) for rapid effect. Antibiotics are administered intravenously. Seizures are controlled with appropriate anticonvulsants, avoiding drugs that require hepatic metabolism.

The World Organisation for Animal Health (WOAH) provides standards for animal health and welfare that include guidelines for the management of animals with chronic diseases, including hepatic disorders (www.woah.org/en/what-we-do/animal-health-and-welfare).

Long-Term Medical Management

For dogs that are not surgical candidates due to financial constraints, severe concurrent disease, or owner preference, long-term medical management is an option. These dogs require lifelong dietary modification, lactulose therapy, and periodic monitoring of bile acids and clinical signs. The prognosis for long-term medical management alone is guarded, as progressive hepatic encephalopathy and urolithiasis are common complications.

Surgical Management

Patient Selection and Timing

Surgical attenuation is the definitive treatment for congenital PSS. Ideal candidates are dogs with a single congenital shunt, adequate portal vein size, and no evidence of portal hypertension. Dogs with acquired shunts are not surgical candidates. Dogs with portal vein hypoplasia or aplasia may still be candidates for attenuation, but the risk of postoperative portal hypertension is higher.

A case report by Balsa et al. (2024) described successful surgical attenuation of portosystemic shunt in a dog with imaging-diagnosed portal vein aplasia, demonstrating that even dogs with challenging vascular anatomy may benefit from surgery (The Canadian Veterinary Journal, 2024, PubMed ID 38304473). However, such cases require careful preoperative planning and intraoperative monitoring.

The optimal timing for surgery is after medical stabilization and before the development of irreversible neurologic damage or severe urolithiasis. Most surgeons recommend surgery between 4 and 8 months of age, but older dogs can also undergo attenuation if they are otherwise healthy.

Surgical Techniques

The goal of surgical attenuation is to gradually occlude the shunt vessel, redirecting portal blood flow through the liver. Complete acute ligation is rarely performed due to the high risk of fatal portal hypertension. Instead, gradual attenuation devices are used.

Ameroid constrictors are the most commonly used device for extrahepatic shunts. The constrictor consists of a stainless steel ring encased in a hygroscopic casein material that swells over time, gradually occluding the shunt. Complete occlusion typically occurs within 4 to 6 weeks. The constrictor is placed around the shunt vessel during surgery, and the abdomen is closed. No further intervention is required.

Cellophane bands are an alternative to ameroid constrictors. The band is placed around the shunt and secured with hemoclips. The cellophane induces an inflammatory reaction that leads to fibrosis and gradual occlusion over 8 to 12 weeks. Cellophane bands are less expensive than ameroid constrictors but require more precise placement to avoid slippage.

For intrahepatic shunts, surgical access is more challenging. A thoracotomy or median sternotomy may be required to access the shunt within the liver parenchyma. Interventional radiology techniques, including transvenous coil embolization or vascular plug placement, are increasingly used for intrahepatic shunts. These techniques are less invasive than open surgery but require specialized equipment and expertise.

Intraoperative Monitoring

Intraoperative measurement of portal pressure is essential during shunt attenuation. A catheter is placed in a jejunal vein or the splenic vein, and baseline portal pressure is measured. The shunt is then temporarily occluded, and portal pressure is measured again. An increase in portal pressure of less than 10 cm H2O is considered safe for complete occlusion. An increase of 10 to 20 cm H2O indicates the need for gradual attenuation. An increase greater than 20 cm H2O suggests that the shunt should not be occluded, and the dog may not be a surgical candidate.

Direct portal pressure measurement is the gold standard, but indirect methods such as splenic pulp pressure measurement can also be used. Intraoperative ultrasound with color flow Doppler can assess portal blood flow direction and velocity.

Postoperative Care

Dogs recovering from shunt attenuation require intensive monitoring for complications. The most common early complication is portal hypertension, which manifests as abdominal pain, vomiting, diarrhea, and signs of shock. Portal hypertension can lead to intestinal ischemia, sepsis, and death if not recognized and treated promptly.

Medical management is continued postoperatively, with gradual weaning of lactulose and antibiotics over 4 to 8 weeks as the shunt occludes. Dietary protein is gradually increased as the liver adapts to increased portal blood flow. Bile acids are measured at 4 to 8 weeks postoperatively to assess shunt occlusion. Complete occlusion is confirmed by normalization of bile acids.

A case report by Smith et al. (2025) described pneumothorax in a dog after surgical attenuation of portosystemic shunt, highlighting the potential for thoracic complications even with abdominal surgery (Veterinary Anaesthesia and Analgesia, 2025, PubMed ID 39986924). This underscores the need for careful postoperative monitoring of respiratory function.

Complications and Failure Patterns

Surgical attenuation of PSS carries a complication rate of 10% to 30%, depending on the shunt type and surgical technique. The most serious complication is acute portal hypertension, which can occur if the shunt is occluded too rapidly or if the portal vein is hypoplastic. Signs of portal hypertension include abdominal distension, pain, vomiting, and diarrhea. Immediate surgical intervention to remove or loosen the attenuation device may be necessary.

Seizures are another common complication, occurring in 5% to 15% of dogs postoperatively. Seizures may be due to hepatic encephalopathy, hypoglycemia, electrolyte imbalances, or cerebral edema. Management includes anticonvulsant therapy, correction of metabolic abnormalities, and supportive care.

Incomplete shunt occlusion occurs in 10% to 20% of cases, particularly with cellophane bands. Dogs with incomplete occlusion may have persistent clinical signs and require repeat imaging and possible revision surgery. Multiple acquired shunts can develop if the original shunt is not completely occluded.

A case report by Tobias and colleagues (2013) described multiple congenital PSS in a dog, emphasizing that not all shunts are single and that thorough preoperative imaging is essential (Journal of the American Animal Hospital Association, 2013, DOI 10.5326/JAAHA-MS-5877).

Prognosis

The prognosis for dogs with congenital PSS that undergo successful surgical attenuation is good to excellent. Most dogs achieve complete shunt occlusion and resolution of clinical signs. Long-term survival is excellent, with many dogs living a normal lifespan.

Factors associated with a poorer prognosis include intrahepatic shunt location, small portal vein size, presence of portal vein hypoplasia or aplasia, and development of postoperative complications. Dogs with intrahepatic shunts have a higher perioperative mortality rate and a lower rate of complete occlusion compared to dogs with extrahepatic shunts.

Dogs managed medically alone have a guarded prognosis. Progressive hepatic encephalopathy, urolithiasis, and hepatic failure are common causes of death or euthanasia. Median survival time for medically managed dogs is 2 to 4 years, compared to 8 to 12 years for surgically treated dogs.

Records and Measurements

Preoperative Documentation

Complete medical records are essential for dogs undergoing PSS evaluation and treatment. The following should be documented:

• Signalment, including breed, age, sex, and weight
• Presenting complaint and duration of clinical signs
• Complete physical examination findings, including neurologic status
• Results of laboratory testing, including biochemistry, CBC, urinalysis, and bile acids
• Imaging findings, including ultrasound and CTA reports
• Medical management plan, including diet, lactulose dose, and antibiotic regimen
• Informed consent for surgery, including discussion of risks and prognosis

Intraoperative Records

Intraoperative records should include:

• Baseline portal pressure
• Portal pressure after temporary shunt occlusion
• Type and size of attenuation device used
• Any complications encountered
• Estimated blood loss
• Anesthetic record, including drugs used and vital parameters

Postoperative Monitoring

Postoperative monitoring should include:

• Daily physical examination, including abdominal palpation and neurologic assessment
• Monitoring for signs of portal hypertension (abdominal pain, vomiting, diarrhea)
• Monitoring for seizures
• Serial bile acid measurements at 4, 8, and 12 weeks postoperatively
• Repeat imaging (ultrasound or CTA) if bile acids do not normalize

Common Failure Patterns

Incomplete Shunt Occlusion

Incomplete occlusion is the most common long-term complication. Causes include improper device placement, device migration, or development of collateral vessels. Dogs with incomplete occlusion may have persistent or recurrent clinical signs. Repeat CTA is indicated to assess shunt patency and plan revision surgery.

Portal Hypertension

Acute portal hypertension is a life-threatening emergency. It occurs when the shunt is occluded too rapidly, causing a sudden increase in portal pressure. The portal vein may be hypoplastic and unable to accommodate the increased blood flow. Treatment involves immediate surgical removal or loosening of the attenuation device. Dogs that survive the acute episode may develop multiple acquired shunts.

Seizures

Postoperative seizures are a common complication, particularly in dogs with preexisting neurologic signs. Seizures may be due to hepatic encephalopathy, hypoglycemia, electrolyte imbalances, or cerebral edema. Management includes anticonvulsant therapy, correction of metabolic abnormalities, and supportive care. Dogs with refractory seizures have a poor prognosis.

Urolithiasis

Ammonium urate uroliths can form before or after surgery. Preoperative uroliths should be removed surgically or via urohydropropulsion. Postoperative uroliths may form if shunt occlusion is incomplete or if the dog remains hyperammonemic. Dietary management and medical dissolution with allopurinol may be attempted, but surgical removal is often necessary.

Welfare and Safety Context

Anesthetic Considerations

Dogs with PSS are at increased risk for anesthetic complications due to impaired hepatic drug metabolism, hypoglycemia, and coagulopathy. Anesthetic protocols should use drugs that are minimally dependent on hepatic metabolism. Propofol, isoflurane, and sevoflurane are preferred. Benzodiazepines and opioids should be used with caution. Blood glucose should be monitored frequently, and dextrose supplementation provided as needed.

Pain Management

Postoperative pain management is essential for recovery. Multimodal analgesia using opioids, non-steroidal anti-inflammatory drugs (with caution due to hepatic metabolism), and local anesthetics is recommended. Pain can exacerbate stress and delay recovery.

Owner Education

Owners should be educated about the signs of portal hypertension, seizures, and other complications. They should be instructed to monitor their dog closely for the first 48 hours after surgery and to seek immediate veterinary care if any concerning signs develop. Long-term follow-up is essential, including periodic bile acid measurements and imaging.

The World Organisation for Animal Health (WOAH) emphasizes the importance of animal welfare in veterinary practice, including the provision of appropriate pain management and owner education (www.woah.org/en/what-we-do/animal-health-and-welfare).

Professional Escalation Criteria

Urgent Escalation

Veterinarians should seek immediate consultation with a veterinary surgeon or internal medicine specialist in the following situations:

• Acute onset of severe neurologic signs (seizures, coma) in a dog with known or suspected PSS
• Signs of portal hypertension after shunt attenuation (abdominal pain, vomiting, diarrhea, shock)
• Postoperative seizures that are refractory to initial anticonvulsant therapy
• Suspected anesthetic complication in a dog with PSS

Routine Escalation

Referral to a specialist is recommended for:

• Initial diagnosis and surgical planning for congenital PSS
• Dogs with complex shunt anatomy (intrahepatic, multiple shunts, portal vein aplasia)
• Dogs with incomplete shunt occlusion after initial surgery
• Dogs with recurrent clinical signs after medical management

Practical Decision Framework for Shunt Attenuation: Selecting Approach, Device, and Monitoring Protocol

Selecting the appropriate surgical approach and attenuation device for a canine portosystemic shunt requires a structured decision process that integrates preoperative imaging findings, intraoperative measurements, and patient-specific risk factors. A systematic framework helps clinicians avoid common errors such as selecting an inappropriate device for the shunt anatomy, misjudging portal vein capacity, or failing to recognize contraindications to attenuation. This section provides a practical decision framework that complements the general surgical descriptions in the preceding sections, with emphasis on concrete criteria that can be applied in clinical practice.

Preoperative Decision Algorithm

The first decision point is determining whether the shunt is amenable to surgical attenuation. Absolute contraindications include acquired multiple shunts secondary to chronic liver disease, severe portal vein hypoplasia with a portal vein diameter less than 2 mm on CT angiography, and uncorrectable coagulopathy. Relative contraindications include severe hepatic encephalopathy that does not respond to medical management, concurrent portosystemic shunt with other congenital anomalies that carry a poor prognosis, and owner inability to provide postoperative care.

For congenital shunts deemed surgical candidates, the next decision is the approach based on shunt location. Extrahepatic shunts are approached via midline celiotomy. Intrahepatic shunts require either thoracotomy, median sternotomy, or interventional radiology techniques. The choice between open surgery and interventional radiology depends on available equipment, operator expertise, and shunt anatomy. The multi-institutional study by the Society of Veterinary Soft Tissue Surgery and the Veterinary Interventional Radiology and Interventional Endoscopy Society classified extrahepatic shunts in 1082 dogs based on CT angiography, providing a standardized nomenclature that facilitates surgical planning (Veterinary Radiology & Ultrasound, 2024, PubMed ID 39102361). This classification system divides extrahepatic shunts into types based on their origin from the portal vein or its tributaries and their insertion into the systemic circulation.

For intrahepatic shunts, CT angiography is essential for determining the insertion point. Bertolini et al. (2020) demonstrated that canine intrahepatic portosystemic shunt insertion into the systemic circulation is commonly through primary hepatic veins as assessed with CT angiography (Veterinary Radiology & Ultrasound, 2020, PubMed ID 32663370). This finding has direct surgical implications: shunts that insert into the caudal vena cava via a hepatic vein may be amenable to attenuation via a thoracotomy approach, while those that insert directly into the caudal vena cava may require a different approach.

Device Selection Criteria

The choice between ameroid constrictor and cellophane band depends on several factors. Ameroid constrictors provide more predictable and rapid occlusion, typically achieving complete closure within 4 to 6 weeks. They are the preferred device for most extrahepatic shunts and for intrahepatic shunts when surgical access allows placement. Cellophane bands are a reasonable alternative when ameroid constrictors are not available or when the shunt anatomy does not accommodate a constrictor. Cellophane bands induce fibrosis over 8 to 12 weeks and require more precise placement to prevent migration.

For intrahepatic shunts, interventional radiology techniques such as transvenous coil embolization or vascular plug placement are increasingly used. These techniques require specialized equipment and training but offer the advantage of avoiding thoracotomy. The decision to use interventional radiology versus open surgery depends on the shunt diameter, length, and angle of insertion, as determined by CT angiography.

Intraoperative Decision Points

Intraoperative portal pressure measurement is the critical decision point during shunt attenuation. The protocol involves placing a catheter in a jejunal vein or the splenic vein and measuring baseline portal pressure. Normal portal pressure in dogs is 5 to 10 cm H2O. After temporary shunt occlusion, portal pressure is measured again. The following thresholds guide decision-making:

• Increase less than 10 cm H2O: Safe for complete occlusion with ameroid constrictor or cellophane band
• Increase of 10 to 20 cm H2O: Use gradual attenuation device, consider partial occlusion initially
• Increase greater than 20 cm H2O: Abort attenuation, dog may not be a surgical candidate

Direct portal pressure measurement is the gold standard, but indirect methods such as splenic pulp pressure measurement can be used when direct catheterization is not feasible. Intraoperative ultrasound with color flow Doppler can assess portal blood flow direction and velocity, providing additional information about the hemodynamic consequences of shunt occlusion.

Postoperative Monitoring Protocol

The postoperative monitoring protocol should be standardized to detect complications early. The following schedule is recommended:

• First 24 hours: Intensive care monitoring with hourly assessment of heart rate, respiratory rate, blood pressure, and neurologic status. Monitor for signs of portal hypertension including abdominal pain, vomiting, diarrhea, and signs of shock.
• Days 2 to 7: Twice daily physical examination, including abdominal palpation and neurologic assessment. Monitor for seizures, which occur in 5% to 15% of dogs postoperatively.
• Weeks 2 to 4: Gradual weaning of lactulose and antibiotics as the shunt occludes. Increase dietary protein gradually as the liver adapts to increased portal blood flow.
• Weeks 4 to 8: Measure fasting and postprandial bile acids to assess shunt occlusion. Complete occlusion is confirmed by normalization of bile acids.
• Months 3 to 6: Repeat bile acid measurement and consider repeat imaging if bile acids remain elevated.

A case report by Smith et al. (2025) described pneumothorax in a dog after surgical attenuation of portosystemic shunt, highlighting the potential for thoracic complications even with abdominal surgery (Veterinary Anaesthesia and Analgesia, 2025, PubMed ID 39986924). This underscores the need for careful postoperative monitoring of respiratory function, including auscultation and thoracic radiographs if respiratory signs develop.

Record System for Shunt Attenuation Cases

A standardized record system facilitates consistent documentation and outcome assessment. The following elements should be recorded for each case:

Preoperative Records

• Signalment: breed, age, sex, weight
• Presenting complaint and duration of clinical signs
• Physical examination findings, including neurologic status
• Laboratory results: biochemistry, CBC, urinalysis, fasting and postprandial bile acids
• Imaging findings: ultrasound report, CT angiography report with shunt classification
• Medical management: diet type, lactulose dose, antibiotic regimen
• Informed consent: discussion of risks, prognosis, and alternative treatments

Intraoperative Records

• Baseline portal pressure
• Portal pressure after temporary shunt occlusion
• Type and size of attenuation device used
• Device placement location relative to shunt anatomy
• Any complications encountered
• Estimated blood loss
• Anesthetic record: drugs used, vital parameters, blood glucose measurements

Postoperative Records

• Daily physical examination findings for first 7 days
• Neurologic status assessment
• Signs of portal hypertension or other complications
• Seizure activity and anticonvulsant therapy if needed
• Bile acid measurements at 4, 8, and 12 weeks
• Repeat imaging results if performed
• Long-term follow-up: clinical status, diet, medications

Troubleshooting Common Problems

Incomplete Shunt Occlusion

Incomplete occlusion occurs in 10% to 20% of cases, particularly with cellophane bands. Causes include improper device placement, device migration, or development of collateral vessels. Dogs with incomplete occlusion may have persistent or recurrent clinical signs. Repeat CT angiography is indicated to assess shunt patency and plan revision surgery. Options for revision include placement of a second attenuation device, conversion to ameroid constrictor if cellophane band was used initially, or interventional radiology techniques.

Portal Hypertension

Acute portal hypertension is a life-threatening emergency. Signs include abdominal pain, vomiting, diarrhea, and signs of shock. Immediate surgical intervention to remove or loosen the attenuation device may be necessary. Dogs that survive the acute episode may develop multiple acquired shunts. Prevention relies on careful intraoperative portal pressure measurement and appropriate device selection.

Postoperative Seizures

Seizures occur in 5% to 15% of dogs postoperatively. Causes include hepatic encephalopathy, hypoglycemia, electrolyte imbalances, or cerebral edema. Management includes anticonvulsant therapy, correction of metabolic abnormalities, and supportive care. Dogs with refractory seizures have a poor prognosis. Prevention includes preoperative stabilization with medical therapy and careful anesthetic management.

Urolithiasis

Ammonium urate uroliths can form before or after surgery. Preoperative uroliths should be removed surgically or via urohydropropulsion. Postoperative uroliths may form if shunt occlusion is incomplete or if the dog remains hyperammonemic. Dietary management and medical dissolution with allopurinol may be attempted, but surgical removal is often necessary.

Professional Escalation Criteria

Urgent Escalation

Veterinarians should seek immediate consultation with a veterinary surgeon or internal medicine specialist in the following situations:

• Acute onset of severe neurologic signs (seizures, coma) in a dog with known or suspected PSS
• Signs of portal hypertension after shunt attenuation (abdominal pain, vomiting, diarrhea, shock)
• Postoperative seizures that are refractory to initial anticonvulsant therapy
• Suspected anesthetic complication in a dog with PSS

Routine Escalation

Referral to a specialist is recommended for:

• Initial diagnosis and surgical planning for congenital PSS
• Dogs with complex shunt anatomy (intrahepatic, multiple shunts, portal vein aplasia)
• Dogs with incomplete shunt occlusion after initial surgery
• Dogs with recurrent clinical signs after medical management

The American College of Veterinary Internal Medicine (ACVIM) offers consensus statements and guidelines for the diagnosis and management of hepatobiliary disease in small animals (www.acvim.org). The American Animal Hospital Association (AAHA) provides resources on breed-specific health conditions and screening recommendations for veterinary practices (www.aaha.org/resources). The Merck Veterinary Manual provides a comprehensive overview of liver disorders in dogs, including portosystemic shunts, and is a standard reference for veterinary practitioners (Merck Veterinary Manual, www.merckvetmanual.com). The World Organisation for Animal Health (WOAH) provides standards for animal health and welfare that include guidelines for the management of animals with chronic diseases, including hepatic disorders (www.woah.org/en/what-we-do/animal-health-and-welfare).

Common Failure Patterns

Incomplete Shunt Occlusion

Incomplete occlusion is the most common long-term complication. Causes include improper device placement, device migration, or development of collateral vessels. Dogs with incomplete occlusion may have persistent or recurrent clinical signs. Repeat CTA is indicated to assess shunt patency and plan revision surgery.

Portal Hypertension

Acute portal hypertension is a life-threatening emergency. It occurs when the shunt is occluded too rapidly, causing a sudden increase in portal pressure. The portal vein may be hypoplastic and unable to accommodate the increased blood flow. Treatment involves immediate surgical removal or loosening of the attenuation device. Dogs that survive the acute episode may develop multiple acquired shunts.

Seizures

Postoperative seizures are a common complication, particularly in dogs with preexisting neurologic signs. Seizures may be due to hepatic encephalopathy, hypoglycemia, electrolyte imbalances, or cerebral edema. Management includes anticonvulsant therapy, correction of metabolic abnormalities, and supportive care. Dogs with refractory seizures have a poor prognosis.

Urolithiasis

Ammonium urate uroliths can form before or after surgery. Preoperative uroliths should be removed surgically or via urohydropropulsion. Postoperative uroliths may form if shunt occlusion is incomplete or if the dog remains hyperammonemic. Dietary management and medical dissolution with allopurinol may be attempted, but surgical removal is often necessary.

Welfare and Safety Context

Anesthetic Considerations

Dogs with PSS are at increased risk for anesthetic complications due to impaired hepatic drug metabolism, hypoglycemia, and coagulopathy. Anesthetic protocols should use drugs that are minimally dependent on hepatic metabolism. Propofol, isoflurane, and sevoflurane are preferred. Benzodiazepines and opioids should be used with caution. Blood glucose should be monitored frequently, and dextrose supplementation provided as needed.

Pain Management

Postoperative pain management is essential for recovery. Multimodal analgesia using opioids, non-steroidal anti-inflammatory drugs (with caution due to hepatic metabolism), and local anesthetics is recommended. Pain can exacerbate stress and delay recovery.

Owner Education

Owners should be educated about the signs of portal hypertension, seizures, and other complications. They should be instructed to monitor their dog closely for the first 48 hours after surgery and to seek immediate veterinary care if any concerning signs develop. Long-term follow-up is essential, including periodic bile acid measurements and imaging.

The World Organisation for Animal Health (WOAH) emphasizes the importance of animal welfare in veterinary practice, including the provision of appropriate pain management and owner education (www.woah.org/en/what-we-do/animal-health-and-welfare).

Frequently Asked Questions

What is the difference between congenital and acquired portosystemic shunts?

Congenital shunts are present at birth and result from abnormal vascular development. They are single vessels that connect the portal vein to the systemic circulation. Acquired shunts develop later in life secondary to chronic liver disease and portal hypertension. They are multiple, tortuous vessels that form as collateral circulation. Congenital shunts are amenable to surgical attenuation, while acquired shunts are not.

How is a portosystemic shunt diagnosed in dogs?

Diagnosis begins with laboratory testing, including fasting and postprandial bile acids. Abdominal ultrasound is the first-line imaging modality, but computed tomography angiography (CTA) is the gold standard for definitive diagnosis and surgical planning. CTA provides three-dimensional reconstruction of the vasculature, allowing precise identification of the shunt anatomy.

What are the clinical signs of a liver shunt in dogs?

Clinical signs include stunted growth, poor body condition, and intermittent neurologic signs such as lethargy, ataxia, circling, head pressing, blindness, seizures, and coma. Gastrointestinal signs include vomiting, diarrhea, and ptyalism. Urinary signs include pollakiuria, hematuria, and stranguria due to ammonium urate urolithiasis.

Can a dog with a portosystemic shunt be managed without surgery?

Yes, long-term medical management is an option for dogs that are not surgical candidates. Medical management includes dietary modification with a low-protein diet, lactulose therapy, and antibiotics. However, the prognosis for medical management alone is guarded, with median survival times of 2 to 4 years compared to 8 to 12 years for surgically treated dogs.

What is the success rate of surgical attenuation for portosystemic shunts?

The success rate depends on the shunt type and surgical technique. For extrahepatic shunts, complete occlusion rates of 80% to 90% are reported with ameroid constrictors. For intrahepatic shunts, success rates are lower, ranging from 60% to 80%. Dogs that achieve complete occlusion have an excellent long-term prognosis.

What are the risks of surgery for portosystemic shunts?

The most serious risk is acute portal hypertension, which can occur if the shunt is occluded too rapidly. Other risks include seizures, incomplete shunt occlusion, hemorrhage, infection, and anesthetic complications. The overall complication rate is 10% to 30%, depending on the shunt type and surgical technique.

How long does recovery take after shunt attenuation surgery?

Most dogs require 2 to 4 weeks of restricted activity after surgery. Medical management is continued postoperatively, with gradual weaning of lactulose and antibiotics over 4 to 8 weeks. Bile acids are measured at 4 to 8 weeks to assess shunt occlusion. Complete recovery and normalization of liver function may take several months.

What is the prognosis for a dog with a portosystemic shunt?

The prognosis for dogs that undergo successful surgical attenuation is good to excellent, with many dogs living a normal lifespan. Factors associated with a poorer prognosis include intrahepatic shunt location, small portal vein size, and development of postoperative complications. Dogs managed medically alone have a guarded prognosis.

Related Veterinary Guides

• Dog
• Canine Hyperadrenocorticism Cushings Diagnostic Management
• Dog Shedding Management
• How To Skin A Dog
• Arthritis In Dogs Symptoms And Diagnosis

References and Further Reading

• www.merckvetmanual.com
• www.aaha.org
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Ultrasonographic diagnosis of portosystemic shunting in dogs and cats.. Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association, 2004.
• Canine intrahepatic portosystemic shunt insertion into the systemic circulation is commonly through primary hepatic veins as assessed with CT angiography.. Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association, 2020.
• Anatomy of extrahepatic portosystemic shunts in dogs as determined by computed tomography angiography.. Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association, 2011.
• Successful surgical attenuation of portosystemic shunt in a dog with imaging-diagnosed portal vein aplasia.. The Canadian veterinary journal = La revue veterinaire canadienne, 2024.
• Anatomical classification of canine congenital extrahepatic portosystemic shunts based on CT angiography: A SVSTS and VIRIES multi-institutional study in 1082 dogs.. Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association, 2024.
• Pneumothorax in a dog after surgical attenuation of portosystemic shunt.. Veterinary anaesthesia and analgesia, 2025.
• Congenital partial pericardial defect affecting the right ventricle in a dog.. Journal of Veterinary Cardiology, 2025.
• Multiple congenital PSS in a dog: case report and literature review.. The Journal of the American Animal Hospital Association, 2013.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.